(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 73.74% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Ocular Therapeutix's revenue in 2026 is $51,951,000.On average, 15 Wall Street analysts forecast OCUL's revenue for 2026 to be $12,206,631,124, with the lowest OCUL revenue forecast at $11,093,573,058, and the highest OCUL revenue forecast at $13,486,005,709. On average, 13 Wall Street analysts forecast OCUL's revenue for 2027 to be $23,680,511,720, with the lowest OCUL revenue forecast at $11,306,911,001, and the highest OCUL revenue forecast at $63,315,653,922.
In 2028, OCUL is forecast to generate $66,483,069,307 in revenue, with the lowest revenue forecast at $23,423,635,420 and the highest revenue forecast at $133,906,567,098.